

Joint working executive summary

Project title	Executive summary of a joint-working agreement between the Academic Health Science Network for the North East and North Cumbria (AHSN NENC) and Sanofi – Improving the identification and treatment of patients with Familial Hypercholesterolemia in primary care
Partner organisation/s	Academic Health Science Network for the North East and North Cumbria (AHSN NENC) Sanofi
Project rationale	The Academic Health Science Network for the North East and North Cumbria (AHSN NENC) is dedicated to improving healthcare, driving wealth creation and promoting research participation across the region. AHSN NENC has numerous member organisations including 13 Foundation trusts, 12 CCGs and 6 higher education institutions.
	Sanofi and AHSN NENC are working in partnership under a joint working agreement to facilitate better identification of patients within primary care who may be at risk of having Familial Hypercholesterolaemia (FH) or high cardiovascular (CV) risk. The project will consist of a baseline audit to identify patients who have or may be at risk of FH or high CV risk using an audit system provided by a third party supplier. Patient reviews will follow which will be delivered by the NHS and the majority of these will take place in primary care. Any clinical interventions that take place will be implemented in line with local guidelines and pathways. The audit tool will be utilised at various time intervals to measure the impact of the project. Patient and healthcare professional questionnaires will be used to measure the impact of any teaching or training interventions.
	Progress of the project will be tracked by a designated project team which will consist of members both from NENC AHSN, Newcastle Hospitals NHS Foundation Trust, relevant CCG members and Sanofi. The overall project delivery will be overseen by a project manager.
Project period	Phase 1 of this project finished in quarter 2 2020.

	Anticipated finished date for phase 2 of the project is January 2025.
Project objectives	For the Patient
	 Delivery of optimised care in line with local guidelines (and in line with nationally accepted guidance) Prompt assessment and earlier access to the most appropriate treatments A more convenient service model which will improve patient experience and understanding of the disease
	For the NHS
	 Better identification and data recording of patients with FH or high CV risk Specific training for healthcare professionals within primary care to enhance their skills when dealing with a patient who has FH and / or high CV risk Improvement in unplanned admissions and local medicines optimisation
	For Sanofi
	 Appropriate use of Sanofi medicines, in line with local guidance.
Contact details	NHS: Professor Julie Newton Chief Medical Officer AHSN NENC Biomedical Research Building, The Campus for Ageing and Vitality, Nuns' Moor Road, Newcastle upon Tyne, NE4 5PL Tel - 0191 208 1326
	Sanofi: Fleur Chandler

Director of Patient Access
Sanofi
410 Thames Valley Park Drive
Reading
Berks, RG6 1PT
Tel – (0) 1183 543 000